位元堂继续推进对产品创新的承诺，例如今年夏天成功推出户外和数码推广活动相结合的位元堂祛湿清 营销活动。位元堂祛湿清已迅速成为最畅销的保健品，带来显著的销售增长。为进一步巩固集团在非处 方药产品市场的领导地位，集团将于即将到来的秋冬季节针对旗舰产品安宫牛黄丸及猴枣除痰散推出全 新营销活动。 随着大湾区简化中成药审批流程的公布，公司的专业团队一直与中国相关部门展开紧密合作。集团欣然 宣布，猴枣除痰散已根据此流程获批为香港首个OTC产品。此项成就将于明年起让中国内地数以百万计 的消费者得以便捷获得猴枣除痰散。 格隆汇11月24日丨位元堂(00897.HK)公告，截至2025年9月30日止6个月，集团总收益同比减少约6.9%至 约3.23亿港元，乃主要由于中药及西药及保健食品产品的销售业绩减弱。集团录得母公司拥有人应占溢 利约280万港元(截至2024年9月30日止6个月：约2370万港元)。该减少乃主要由于零售市场消费意欲疲 弱导致收益下降约6.9%，继而导致集团毛利减少、出售物业收益净额大幅下跌，以及投资物业公平值 收益净额减少。每股盈利0.25港仙。 ...

Core Viewpoint - The article emphasizes the health risks associated with expired medications, highlighting misconceptions about their safety and efficacy, particularly regarding both Western and traditional Chinese medicines [1][2][3]. Group 1: Misconceptions about Expired Medications - There is a prevalent belief that expired medications are safe to consume if they have not visibly changed, which is incorrect [1]. - Some individuals think that Western medicines have expiration dates while traditional Chinese medicines do not, which is misleading [1][3]. Group 2: Health Risks of Expired Medications - Expired medications can not only lose their effectiveness but may also undergo chemical changes that produce harmful substances [2]. - For instance, expired antibiotics may lose their ability to combat infections, potentially worsening health conditions [2]. - Certain medications, like aspirin, can decompose into harmful compounds that may cause gastrointestinal issues [2]. Group 3: Regulations and Storage of Traditional Chinese Medicine - The National Medical Products Administration has mandated that traditional Chinese medicine products must display expiration dates starting August 1, 2025, to ensure safety and efficacy [3]. - Proper storage of traditional Chinese medicines is crucial, as improper conditions can lead to spoilage and loss of effectiveness [3][8]. Group 4: Importance of Proper Storage - Effective storage conditions are essential for maintaining the safety and efficacy of medications, with specific temperature and humidity requirements [7]. - Medications should be stored according to their instructions, and opened products should be used within a specified timeframe to avoid contamination [6][7]. Group 5: Recommendations for Home Medicine Management - Regularly cleaning out home medicine cabinets and disposing of expired or spoiled medications is advised [8]. - Traditional Chinese medicines should be categorized and stored appropriately to prevent moisture and pest damage [8].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603858 证券简称：步长制药公告编号：2025-217 山东步长制药股份有限公司 关于公司拟购买安宫牛黄丸药品生产 技术相关事宜的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、交易概述 山东步长制药股份有限公司（以下简称"公司"或"步长制药"）于2023年4月14日召开第四届董事会第三 十四次会议，审议通过了《关于公司拟购买安宫牛黄丸药品生产技术相关事宜的议案》，根据公司发展 战略的实际需要，为丰富公司产品，公司拟以840万元受让辽宁汉草堂中药有限公司（以下简称"辽宁汉 草堂"）拥有的安宫牛黄丸药品生产技术。具体内容详见公司2023年4月15日披露于上海证券交易所网站 （www.sse.com.cn）的《关于公司拟购买安宫牛黄丸药品生产技术相关事宜的公告》（公告编号： 2023-056）。 2023年4月21日，公司与辽宁汉草堂正式签订了《药品上市许可持有人变更和药品生产场地变更技术合 同》，具体内容详见公司2023年4月22日披露于上海证券交易所 ...

Policy Developments - The National Medical Products Administration (NMPA) is focusing on the quality supervision of selected drugs in centralized procurement, emphasizing the importance of quality safety and compliance in production [1] - The NMPA will implement comprehensive production inspections and product sampling for selected drugs, optimizing work mechanisms and exploring risk monitoring [1] - The NMPA acknowledges the development of the medical device industry in Chongqing and stresses the need for a robust quality safety responsibility system [2] Drug and Device Approvals - Baiyunshan's subsidiary Zhongyi Pharmaceutical received a registration certificate for the traditional medicine An Gong Niu Huang Wan from Vietnam's Ministry of Health, aiding market expansion [3] - Huyou Pharmaceutical announced that its subsidiary Seacross Pharmaceuticals Ltd. received marketing approvals for multiple products from regulatory authorities in Pakistan, the UK, and North Macedonia [4] - Zhifei Biological's recombinant herpes zoster vaccine (ZFA01) clinical trial application has been accepted by the NMPA, which may enhance vaccine efficacy [5] Capital Market Activities - Puluo Pharmaceutical plans to repurchase shares worth between RMB 180 million and RMB 360 million, with a maximum price of RMB 23 per share [6][7] - Sinovac Biotech received a delisting notice from NASDAQ due to failure to submit its annual report by the deadline, with potential trading suspension imminent [8] Industry Developments - Researchers published a detailed immune response map following pig kidney transplants in brain-dead patient models, identifying key factors for transplant success [9] - Haizheng Pharmaceutical's subsidiary plans to collaborate with the East China Institute for the biomanufacturing of heparin, with a project budget not exceeding RMB 120 million [10] Public Sentiment Alerts - Guangyuyuan announced the resignation of Vice President Wang Junbo due to work adjustments, effective immediately [11] - Medici's shareholder Chen Guoxing plans to reduce his stake by up to 1.64% through trading methods due to personal financial needs [12]

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. has received a drug registration certificate for Angong Niuhuang Pills from the Vietnamese Ministry of Health, which will allow its subsidiary to expand its market presence in Vietnam [1][3]. Group 1: Drug Information - The drug Angong Niuhuang Pills is a prescription traditional Chinese medicine used for clearing heat and detoxifying, as well as calming and opening the orifices [2]. - The registration number for Angong Niuhuang Pills is VNCT-00006-25, and it is manufactured by Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. [1]. Group 2: Financial Performance - In 2024, the sales revenue of Angong Niuhuang Pills in China reached RMB 498,242 million, while the sales revenue for Zhongyi Pharmaceutical was RMB 15,611.83 million [2]. - The total research and development investment for the Angong Niuhuang Pills project by Zhongyi Pharmaceutical has reached approximately RMB 3,279.81 million (unaudited) [2]. Group 3: Market Impact - The registration of Angong Niuhuang Pills is expected to enhance the market competitiveness of the company’s products and facilitate the expansion of its business in Vietnam [3]. - The impact of this registration on the company's current performance is not expected to be significant [3].

Major Events - CICC (03908), Dongxing Securities (601198.SH), and Xinda Securities (601059.SH) plan to merge through absorption and share exchange [1] - Ruian Real Estate (00272) has reached a joint venture arrangement to develop a renewal project in Pudong New District, Shanghai [1] - Baijin Life Sciences (01466) subsidiary intends to invest in Youhuan Bio to create a leading global circRNA technology R&D platform [1] - Code-B (02487) has its new drug application for CU-40105 (self-developed topical finasteride spray) accepted by the National Medical Products Administration [1] - Pony.ai-W (02026) collaborates with SANY Heavy Truck and Dongfeng Liuzhou Motor to jointly develop a fourth-generation autonomous truck family [1] - Qiming Medical-B (02500) announces mid-term clinical results of its innovative transcatheter valve replacement system Cardiovalve from the TARGET study [1] - Wuling Motors (00305) establishes a subsidiary focused on low-speed intelligent driving systems and solutions [1] - Neusoft Ruixin Group (09616) signs a general contracting construction contract with Guangdong College, Chengdu College, and Dalian College [1] - Baiyunshan (00874) receives a drug registration certificate for An Gong Niu Huang Wan from the Vietnam Ministry of Health [1] - Dongfang Electric (01072) and Anhui Energy plan to jointly establish a joint venture to advance the 1 million kilowatt technological innovation experimental wind farm project [1] Operating Performance - Mifus (02556) reports a 45% year-on-year increase in AI+SaaS business revenue for the third quarter [2] - GDS Holdings (09698) reports third-quarter net revenue of 2.887 billion yuan, a year-on-year increase of 10.2% [2] - SF Holding (06936) reports total revenue of 26.454 billion yuan from express logistics, supply chain, and international business in October, a year-on-year increase of 9.79% [2] - Kingsoft Cloud (03896) achieves adjusted net profit of 28.7 million yuan for the first time in the third quarter [2] - Guofu Quantum (00290) issues a positive profit alert, expecting mid-term net profit attributable to shareholders to be approximately 200 to 210 million HKD, turning from loss to profit year-on-year [2] - Kingsoft Software (03888) reports third-quarter profit attributable to shareholders of approximately 213 million yuan, a year-on-year decrease of 48% [2] - Kuaishou-W (01024) reports operating profit of 5.299 billion yuan in the third quarter, a year-on-year increase of 69.9% [2]

财报显示，2025年上半年，化妆品收入仅3.2亿元，同比下滑23.82%，占总收入比重不足6%；以安宫牛 黄丸为主的心脑血管用药，收入则暴跌71.04%，毛利率降至8.94%。 为转嫁成本压力，片仔癀在2023年5月将锭剂零售价从590元/粒，提至760元/粒，涨幅达28.8%，但提价 幅度依然无法覆盖成本升幅。而且，消费端对高价产品的承接力已逼近极限，在经济增速放缓、理性消 费主导的背景下，片仔癀作为高端礼品和"保健奢侈品"的需求锐减。 2024年底，黄牛回收价跌至500元/粒，不仅与4年前品被黄牛炒至1500元/粒的盛况形成鲜明对比，甚至 已低于官方指导价，渠道库存积压严重。这一点，从片仔癀应收账款增速连续多个季度高于营收增速中 就可见一斑。 如今其官方指导价760元的锭剂，在零售渠道实际售价已降至650元左右，临期产品甚至低至350元，提 价策略彻底失效。 如果说提价策略的失效只是表象，那么"单品依赖症"则是更深层次的原因。近年来，片仔癀确实做了多 元化尝试，比如拓展化妆品、医药流通、心脑血管用药等业务，但收效甚微。 2025年10月，曾经市值逼近3000亿元的"药中茅台"片仔癀，交出了一份令市场失望的 ...

本次获得越南卫生部传统药品管理局颁发的安宫牛黄丸药品注册证书后，该药品将由中一药业授权 TNHH NEWSEEN COAST公司在越南地区销售，有助于中一药业扩展越南市场业务，提升本公司产品 市场竞争力。本次获得安宫牛黄丸药品注册证书，对公司当期业绩无重大影响。 智通财经APP讯，白云山(00874)公布，近日，公司全资子公司广州白云山中一药业有限公司(以下简 称"中一药业")收到越南卫生部传统药品管理局签发的安宫牛黄丸注册证书。 该信息由智通财经网提供 ...

中一药业于2024年6月20日向越南卫生部传统药品管理局递交了安宫牛黄丸(Angong Niuhuang Pills)药品 注册申请。安宫牛黄丸的功能主治为清热解毒，镇惊开窍。本次获得越南卫生部传统药品管理局颁发的 安宫牛黄丸药品注册证书后，该药品将由中一药业授权TNHH NEWSEEN COAST公司在越南地区销 售，有助于中一药业扩展越南市场业务，提升公司产品市场竞争力。 格隆汇11月19日丨白云山(00874.HK)发布公告，近日，公司全资子公司广州白云山中一药业有限公司 (以下简称"中一药业")收到越南卫生部传统药品管理局签发的安宫牛黄丸注册证书。 ...

本次获得越南卫生部传统药品管理局颁发的安宫牛黄丸药品注册证书后，该药品将由中一药业授权 TNHH NEWSEEN COAST公司在越南地区销售，有助于中一药业扩展越南市场业务，提升本公司产品 市场竞争力。本次获得安宫牛黄丸药品注册证书，对公司当期业绩无重大影响。 白云山(00874)公布，近日，公司全资子公司广州白云山中一药业有限公司(以下简称"中一药业")收到越 南卫生部传统药品管理局签发的安宫牛黄丸注册证书。 ...